List of Excipients in Branded Drug BLOXIVERZ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Exela Pharma Sciences LLC	BLOXIVERZ	neostigmine methylsulfate	51754-1210	ACETIC ACID
Exela Pharma Sciences LLC	BLOXIVERZ	neostigmine methylsulfate	51754-1210	PHENOL
Exela Pharma Sciences LLC	BLOXIVERZ	neostigmine methylsulfate	51754-1210	SODIUM ACETATE
Exela Pharma Sciences LLC	BLOXIVERZ	neostigmine methylsulfate	51754-1210	SODIUM HYDROXIDE

BLOXIVERZ Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

BLOXIVERZ is a preservative-free injectable formulation of neostigmine methylsulfate used to reverse the effects of nondepolarizing neuromuscular blocking agents after surgery. Its excipient profile is deliberately narrow: sodium chloride for tonicity, citrate components for pH control, and water for injection. Commercial opportunities center on ready-to-use presentations, dose standardization, syringe-based workflow, supply reliability, and differentiated stability rather than novel pharmacology.[1]

What is BLOXIVERZ and how is it formulated?

BLOXIVERZ contains neostigmine methylsulfate at 0.5 mg/mL or 1 mg/mL. The labeled inactive ingredients are sodium chloride, sodium citrate dihydrate, citric acid monohydrate, and water for injection.[1]

Attribute	BLOXIVERZ profile
Active ingredient	Neostigmine methylsulfate
Dosage form	Sterile injectable solution
Strengths	0.5 mg/mL and 1 mg/mL
Route	Intravenous administration
Indication	Reversal of nondepolarizing neuromuscular blockade
Preservative	Preservative-free
Tonicity excipient	Sodium chloride
Buffer system	Citric acid and sodium citrate
Diluent	Water for injection
FDA application	NDA 204078
Approval date	July 31, 2013

The formulation is chemically simple but operationally sensitive. Neostigmine is a potent, water-soluble quaternary ammonium compound. The principal formulation variables are pH, ionic strength, concentration, container compatibility, particulate control, and sterility assurance.

What excipients are used in BLOXIVERZ?

The core excipient strategy has four functions:

Excipient	Primary function	Commercial and technical relevance
Sodium chloride	Adjusts osmolality	Supports intravenous tolerability and reduces the need for pharmacy manipulation
Sodium citrate dihydrate	Buffer component and pH control	Helps maintain solution stability within the labeled pH range
Citric acid monohydrate	Acidic buffer component	Works with citrate to control pH
Water for injection	Vehicle	Supports a simple, low-excipient parenteral system

The absence of antimicrobial preservatives is important. BLOXIVERZ is supplied as a sterile injectable product for clinical use, where preservative-free presentation reduces exposure to benzyl alcohol, parabens, chlorobutanol, and other antimicrobial agents. A preservative-free formulation also supports use in operating-room settings where the product is administered intravenously and dose precision is important.[1]

The formulation does not rely on surfactants, co-solvents, complexing agents, antioxidants, or polymeric stabilizers. That limits excipient-related toxicology and simplifies regulatory justification.

Why is the citrate buffer commercially relevant?

The citrate system provides a controllable pH environment without adding a large excipient burden. For an injectable product, the buffer must balance several competing requirements:

• Maintain chemical stability during shelf life.
• Limit irritation from excessive acidity or alkalinity.
• Avoid precipitation or visible particulates.
• Preserve compatibility with the vial, stopper, syringe, and infusion components.
• Maintain a reproducible pH across manufacturing lots.

A competitor could seek differentiation through a different buffer system, such as phosphate or acetate, but substitution would require comparative stability, compatibility, and safety data. A new buffer is not automatically an improvement. It could alter degradation pathways, container interaction, osmolality, or intravenous tolerability.

The strongest excipient opportunity is therefore not a simple buffer swap. It is a validated formulation and presentation that improves storage, administration, or manufacturing performance while maintaining the established safety profile.

What formulation opportunities exist for BLOXIVERZ competitors?

Ready-to-use prefilled syringes

The most commercially attractive opportunity is a ready-to-use prefilled syringe. Operating rooms and post-anesthesia care units value reduced preparation time, lower medication-error risk, and standardized dosing. A prefilled syringe could compete against vial withdrawal and pharmacy preparation.

Development issues include:

• Syringe material compatibility.
• Extractables and leachables.
• Stopper or plunger interaction.
• Silicone oil levels.
• Subvisible particles.
• Sterilization and terminal processing.
• Delivered-volume accuracy.
• Long-term stability in the filled syringe.

A prefilled syringe may support a premium price if it reduces preparation labor and medication waste. The value proposition is strongest for hospitals with high surgical volume and formal injectable standardization programs.

Ready-to-administer diluted presentations

Neostigmine administration may require dose calculation based on body weight and the degree of neuromuscular blockade. A product with a standardized lower concentration or a ready-to-administer volume could reduce dilution steps. The tradeoff is increased SKU complexity and a larger risk of dosing confusion if several concentrations are stocked.

A commercial portfolio could use differentiated labels and packaging for:

• Adult operating-room use.
• Pediatric or low-weight patients.
• Standard reversal doses.
• Emergency anesthesia carts.
• Institutional protocol-based dosing.

Dual-strength packaging

BLOXIVERZ already uses two concentrations, which supports dose flexibility. A competitor could improve usability through visual differentiation, barcode-enabled packaging, and unit-dose cartons. This is a practical defense against medication errors and can influence hospital formulary decisions even when the active ingredient is identical.

Enhanced stability

Stability improvements could support distribution into facilities with constrained pharmacy capacity or more variable temperature exposure. Any such claim would require real-time and accelerated stability data under applicable FDA requirements. A longer shelf life or broader labeled storage condition could create procurement value, but it would need to be demonstrated rather than inferred from excipient selection.

Alternative container-closure systems

A ready-to-use ampule, polymer vial, cartridge, or cyclic olefin polymer syringe could provide manufacturing or handling advantages. The relevant development risks include adsorption, permeability, particulate generation, and extractables. Glass remains familiar to hospital buyers, but polymer systems may support automated filling and integrated delivery devices.

How does BLOXIVERZ compare with other neostigmine injection products?

BLOXIVERZ competes in a mature injectable market where the active ingredient is generally undifferentiated. The competitive factors are formulation, concentration, packaging, supply continuity, price, and hospital contracting.

Competitive factor	BLOXIVERZ position	Potential competitor advantage
Preservative-free formulation	Strong baseline position	Match the profile and differentiate in delivery
Two strengths	Supports clinical flexibility	Add unit-dose or prefilled formats
Simple excipient system	Low formulation complexity	Use the same platform with improved packaging
Hospital workflow	Vial-based administration	Ready-to-use syringe or cartridge
Clinical differentiation	Limited	Focus on safety, labeling, and administration
Manufacturing differentiation	Conventional sterile injectable	Improve fill-finish efficiency and supply resilience
Pricing	Exposed to injectable competition	Compete through lower cost or reduced total handling cost

The product category is vulnerable to price erosion because neostigmine is an established small molecule and the formulation has no biologic manufacturing barrier. Commercial durability depends more on manufacturing execution and distribution than on active-ingredient exclusivity.

What FDA regulatory pathway applies to BLOXIVERZ competitors?

A generic neostigmine methylsulfate injection would generally proceed through an abbreviated new drug application if the reference-product and product-specific requirements are met. A formulation or presentation with material differences may require a 505(b)(2) application.

Key regulatory questions include:

1. Is the proposed product pharmaceutically equivalent to the reference product?
2. Does the excipient change affect safety, quality, or performance?
3. Is the container closure suitable for a sterile injectable?
4. Are the proposed strengths and concentrations clinically and operationally justified?
5. Does the product require new stability, compatibility, or extractables data?
6. Does a prefilled syringe create device constituent or combination-product requirements?

For injectable products, FDA scrutiny focuses heavily on sterility, particulate matter, endotoxins, visible foreign matter, container closure integrity, manufacturing controls, and stability. Excipient changes can expand the regulatory burden even when the active ingredient remains unchanged.[2][3]

What is the Orange Book and exclusivity status of BLOXIVERZ?

BLOXIVERZ was approved under NDA 204078 on July 31, 2013. The approval followed FDA review of a 505(b)(2) application and included three-year exclusivity associated with clinical investigations supporting approval.[4]

That exclusivity period expired in 2016. BLOXIVERZ therefore does not have a current three-year new-chemical-entity exclusivity barrier. Neostigmine methylsulfate is an established active ingredient, and the principal commercial risk is generic or therapeutically equivalent injectable competition.

Patent protection should be assessed through the current FDA Orange Book and relevant U.S. patent records. The strategic point is that any remaining claim must be distinguished from the product’s expired regulatory exclusivity. Formulation, method-of-use, manufacturing, or device patents could affect a particular competitor even after regulatory exclusivity has ended.

Are Paragraph IV challenges and biosimilar risks relevant?

Paragraph IV litigation is relevant only if an enforceable patent is listed against the reference product and a generic applicant makes the required certification. Because BLOXIVERZ contains a conventional small-molecule active ingredient, the principal competitive threat is an ANDA-based generic rather than a biosimilar.

Biosimilar risk is effectively absent. Neostigmine methylsulfate is not a biologic, and biosimilar approval under the Public Health Service Act is not the applicable pathway. The relevant risks are generic entry, 505(b)(2) reformulation, authorized-generic activity, and hospital purchasing substitution.

Which companies are likely to challenge BLOXIVERZ commercially?

The competitive field includes generic injectable manufacturers, contract manufacturers with sterile fill-finish capacity, and specialty pharmaceutical companies that sell hospital products. Companies with existing injectable portfolios have the clearest advantages because they can share manufacturing, quality, sales, and hospital-contracting infrastructure.

The most credible challengers are likely to compete through:

• Lower acquisition cost.
• Reliable supply during shortages.
• Unit-dose packaging.
• Prefilled syringes.
• Simplified barcode and inventory management.
• Broader institutional contracts.
• Regional distribution strength.

Litigation risk is lower than in high-value oncology or specialty-drug markets because the active ingredient is mature and the addressable revenue pool is narrower. Patent disputes become more important only if a competitor relies on a specific formulation, device, or manufacturing claim.

What manufacturing and intellectual-property barriers protect the product?

The principal barriers are technical rather than pharmacological:

• Sterile fill-finish capability.
• Validated aseptic processing.
• Container-closure integrity.
• Control of visible and subvisible particles.
• Stability in the selected container.
• Consistent pH and osmolality.
• Reliable supply of pharmaceutical-grade components.
• FDA-compliant analytical methods.
• Hospital procurement and distribution access.

A formulation patent covering only sodium chloride, citrate, and water would likely have limited strategic strength unless it claimed a narrow and non-obvious concentration, pH, stability profile, container system, or manufacturing process. Stronger protection would attach to a demonstrably improved presentation, such as a prefilled syringe with defined stability and particulate performance.

What is the commercial revenue opportunity?

BLOXIVERZ is a hospital-use product tied to surgical volume, anesthesia practice, and formulary placement. Revenue is exposed to generic substitution and purchasing pressure. The highest-value opportunities are products that reduce total administration cost rather than merely replicate the vial.

A commercial model should quantify:

• Annual surgical procedures requiring neuromuscular blockade reversal.
• Average neostigmine doses per procedure.
• Vial discard and overfill.
• Pharmacy preparation time.
• Medication-error costs.
• Operating-room inventory requirements.
• Contract pricing and rebate exposure.
• Shortage-related purchasing premiums.
• Conversion potential from vials to prefilled syringes.

A prefilled syringe can justify a higher unit price only if hospitals recognize savings in labor, waste, error prevention, or inventory handling. A low-cost vial remains the most direct generic strategy, but it is also the most exposed to price competition.

Key Takeaways

• BLOXIVERZ uses a simple preservative-free system based on sodium chloride, citrate buffer components, and water for injection.
• The formulation has limited inherent differentiation, so commercial value depends on packaging, supply reliability, and workflow efficiency.
• Prefilled syringes are the clearest product-extension opportunity.
• Unit-dose packaging, barcode integration, and differentiated strengths can improve hospital usability.
• The three-year exclusivity associated with the 2013 approval expired in 2016.
• Generic entry, not biosimilar competition, is the primary market risk.
• Stronger intellectual-property opportunities would likely involve a delivery system, container closure, stability profile, or manufacturing process.
• A premium product must demonstrate lower total hospital handling cost rather than rely on excipient novelty alone.

FAQs

Can BLOXIVERZ be reformulated without citrate?

Yes, but replacing citrate with another buffer would require formulation development, stability testing, container-closure evaluation, and regulatory justification. The alternative buffer would need to preserve solution quality and intravenous tolerability.

Is a preservative-free neostigmine syringe commercially differentiated?

Yes. A preservative-free prefilled syringe can reduce preparation steps and support standardized operating-room workflows. Its commercial advantage depends on stability, syringe compatibility, delivered-dose accuracy, and hospital purchasing economics.

What excipient is most important for BLOXIVERZ stability?

The citrate buffer system is the most important formulation control because pH affects chemical stability, compatibility, and injection tolerability. Sodium chloride primarily supports tonicity.

Could a polymer vial replace the BLOXIVERZ glass container?

Potentially. The replacement would require extractables and leachables testing, container-closure integrity data, particulate assessment, permeability evaluation, and comparative stability studies.

Is an authorized generic the main threat to BLOXIVERZ?

An authorized generic or direct generic injectable could materially reduce pricing and market share. The threat is strongest where products are clinically interchangeable and hospitals purchase primarily through contracts and group purchasing organizations.

References

1. Avadel Pharmaceuticals. (2013). BLOXIVERZ (neostigmine methylsulfate) injection prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2020). ANDAs for certain highly purified synthetic peptides: Guidance for industry. FDA.

3. U.S. Food and Drug Administration. (2015). Container closure systems for packaging human drugs and biologics: Chemistry, manufacturing, and controls documentation. FDA.

4. U.S. Food and Drug Administration. (2013). BLOXIVERZ approval letter, NDA 204078. FDA.